Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Jul;87(7):515-26.
doi: 10.1007/s00277-008-0483-y. Epub 2008 Apr 15.

Cytogenetic features in myelodysplastic syndromes

Affiliations
Review

Cytogenetic features in myelodysplastic syndromes

Detlef Haase. Ann Hematol. 2008 Jul.

Abstract

Myelodysplastic syndromes (MDS) comprise a group of bone marrow diseases characterized by profound heterogeneity in morphologic presentation, clinical course, and cytogenetic features. Roughly 50% of patients display clonal chromosome abnormalities. In several multicentric studies, the karyotype turned out to be one of the most important prognostic parameters and was incorporated into statistical models aiming for a better prediction of the individual prognosis like the International Prognostic Scoring System. However, due to the profound cytogenetic heterogeneity, the impact of many rare abnormalities as well as combinations of anomalies occurring in a substantial portion of patients with MDS is still unknown and can only be delineated on the basis of large international multicentric cooperations. Recently, the German-Austrian MDS Study Group presented cytogenetic findings in 2,072 patients with MDS, which serve as a basis for the characterization of the cytogenetic subgroups discussed in this article. The availability of new therapeutic options for low- and high-risk MDS targeted against distinct entities characterized by specific chromosome abnormalities, like 5q-deletions, monosomy 7, and complex abnormalities underlines the important role of cytogenetics for the clinical management of MDS. This article thus focuses on the clinical and prognostic relevance, the molecular background, and therapeutic perspectives in these three cytogenetic subgroups.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan–Meier survival curves according to the cytogenetic prognostic classification of the German–Austrian MDS Study Group. Log-rank test: p < 0.0001 (3 degrees of freedom) [15]
Fig. 2
Fig. 2
Median survival according to accompanying abnormalities in patients with 5q deletions. Log-rank test: p ≤ 0.0001 (2 degrees of freedom), p = 0.30 (isolated vs. +1), p ≤ 0.0001 (isolated vs. complex), p = 0.0001 (+1 vs. complex)
Fig. 3
Fig. 3
Median survival according to accompanying abnormalities in patients with −7/7q−. Log-rank test: p = 0.03 (2 degrees of freedom), p = 0.94 (isolated vs. +1), p = 0.07 (isolated vs. complex), p = 0.43 (+1 vs. complex)

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1182/blood-2007-03-082404', 'is_inner': False, 'url': 'https://doi.org/10.1182/blood-2007-03-082404'}, {'type': 'PubMed', 'value': '17726160', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/17726160/'}]}
    2. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, Kundgen A, Lubbert M, Kunzmann R, Giagounidis AA, Aul C, Trumper L, Krieger O, Stauder R, Muller TH, Wimazal F, Valent P, Fonatsch C, Steidl C (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110:4385–4395 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '9058730', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/9058730/'}]}
    2. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '16154839', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/16154839/'}]}
    2. Solé F, Luno E, Sanzo C, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Cigudosa JC, Milla F, Ribera JM, Bureo E, Marquez ML, Arranz E, Florensa L (2005) Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 90:1168–1178 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '3860707', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/3860707/'}]}
    2. Knapp RH, Dewald GW, Pierre RV (1985) Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. Mayo Clin Proc 60:507–516 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1002/1097-0142(19861215)58:12<2571::AID-CNCR2820581202>3.0.CO;2-O', 'is_inner': False, 'url': 'https://doi.org/10.1002/1097-0142(19861215)58:12<2571::aid-cncr2820581202>3.0.co;2-o'}, {'type': 'PubMed', 'value': '3779606', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/3779606/'}]}
    2. Nowell PC, Besa EC, Stelmach T, Finan JB (1986) Chromosome studies in preleukemic states. Cancer 58:2571–2575 - PubMed

MeSH terms